Aztreonam: Indications, Dosing, and Renal Adjustments
Indications
Aztreonam is indicated for serious infections caused by aerobic Gram-negative bacteria, particularly when β-lactam alternatives are contraindicated or when targeting specific resistant pathogens. 1
Primary Clinical Uses:
- Urinary tract infections (complicated and uncomplicated)
- Lower respiratory tract infections including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP)
- Intra-abdominal infections (as part of combination therapy with metronidazole for anaerobic coverage)
- Septicemia caused by susceptible Gram-negative organisms
- Skin and skin-structure infections
- Gynecologic infections
Specific Guideline-Supported Scenarios:
For severe β-lactam allergies: Aztreonam is the preferred alternative when treating Gram-negative infections in patients with serious penicillin allergies, as it lacks cross-reactivity with other β-lactams 2, 3.
For ICU pneumonia with penicillin allergy: Use aztreonam plus a respiratory fluoroquinolone for empiric coverage 3, 4, 3.
For complicated intra-abdominal infections: Aztreonam 1-2 g every 6-8 hours is an acceptable option, though it requires combination with metronidazole for anaerobic coverage 2.
For multidrug-resistant organisms: Aztreonam combined with avibactam shows potent activity against metallo-β-lactamase (MBL)-producing Enterobacterales, including NDM and VIM producers, where treatment options are severely limited 5, 6, 7.
Adult Dosing
Standard Dosing (Normal Renal Function)
For most serious systemic infections, administer aztreonam 1-2 g intravenously every 8 hours. 1
| Infection Severity | Dose | Frequency | Route |
|---|---|---|---|
| Urinary tract infections | 500 mg - 1 g | Every 8-12 hours | IV or IM |
| Moderately severe systemic infections | 1-2 g | Every 8-12 hours | IV |
| Severe/life-threatening infections | 2 g | Every 6-8 hours | IV |
| Pseudomonas aeruginosa infections | 2 g | Every 6-8 hours | IV (at least initially) |
Maximum daily dose: 8 g/day 1
Key dosing principle: The intravenous route is mandatory for single doses >1 g or for patients with septicemia, parenchymal abscesses, peritonitis, or other severe infections 1.
Renal Dose Adjustments
Aztreonam requires dose reduction in renal impairment because 60-70% is renally excreted. 1
Creatinine Clearance 10-30 mL/min:
After a standard loading dose (1-2 g), reduce the maintenance dose to 50% of the usual dose at the same interval (every 6,8, or 12 hours). 1
Example: If the usual dose is 2 g every 8 hours, give 2 g loading dose, then 1 g every 8 hours.
Creatinine Clearance <10 mL/min (including hemodialysis):
Give the usual loading dose (500 mg, 1 g, or 2 g), then reduce maintenance to 25% of the initial dose at the usual interval. 1
For hemodialysis patients: Administer an additional 1/8 of the initial dose after each dialysis session 1.
Example: For a 2 g loading dose, give 500 mg every 8 hours, plus 250 mg after each hemodialysis session.
Simplified Hemodialysis Regimen (Evidence-Based Alternative):
For end-stage renal disease patients on hemodialysis, consider simplified once-daily post-dialysis dosing:
- 1 g once daily after hemodialysis achieves >90% target attainment for MICs ≤4 mg/L
- 2 g once daily after hemodialysis achieves >90% target attainment for MICs ≤8 mg/L 8
Important caveat: Thrice-weekly dosing should be avoided except for non-severe infections with MICs ≤0.5 mg/L 8.
Estimating Creatinine Clearance:
When only serum creatinine is available, use the Cockcroft-Gault equation 1:
Males: CrCl = [weight (kg) × (140 - age)] / [72 × serum creatinine (mg/dL)]
Females: CrCl = 0.85 × male value
Pediatric Dosing
Administer aztreonam intravenously to pediatric patients (≥1 month old) with normal renal function. 1
| Infection Severity | Dose | Frequency |
|---|---|---|
| Mild to moderate infections | 30 mg/kg | Every 8 hours |
| Moderate to severe infections | 30 mg/kg | Every 6-8 hours |
Maximum daily dose: 120 mg/kg/day 1
Critical limitation: Insufficient data exist for intramuscular administration in children or for dosing in pediatric patients with renal impairment 1.
Neonatal Considerations:
For complicated intra-abdominal infections in neonates, aztreonam is not specifically recommended in current guidelines. Alternative regimens (ampicillin + gentamicin + metronidazole or meropenem) are preferred 2.
Pharmacokinetic Considerations
Key Parameters:
- Half-life: 1.7 hours (normal renal function); increases to 6 hours in anephric patients 1, 9
- Protein binding: 56% 1
- Volume of distribution: 12.6 L (approximately extracellular fluid volume) 1
- Renal clearance: 56 mL/min (accounts for ~60% of total clearance) 1
Tissue Penetration:
Aztreonam achieves therapeutic concentrations in:
- Bile (39 mcg/mL)
- Pleural fluid (51 mcg/mL)
- Synovial fluid (83 mcg/mL)
- Lung tissue (22 mcg/g)
- CSF in inflamed meninges (3 mcg/mL) 1
For meningitis: CSF penetration is adequate for E. coli and H. influenzae but decreases as inflammation resolves 10.
Duration of Therapy
Continue aztreonam for at least 48 hours after the patient becomes afebrile or shows evidence of bacterial eradication. 1
Persistent infections may require several weeks of treatment. The specific duration depends on infection severity and clinical response 1.
Monitoring Requirements
Weekly monitoring during outpatient parenteral therapy should include: 11
- Complete blood count (once weekly)
- Renal function tests (once weekly)
- Clinical assessment at each visit
No routine serum drug level monitoring is required for aztreonam, unlike aminoglycosides 11.
Common Pitfalls and Caveats
Anaerobic coverage: Aztreonam has NO activity against anaerobes or Gram-positive organisms. Always combine with metronidazole for intra-abdominal infections 2.
Pseudomonas resistance: Resistance can emerge during therapy. For P. aeruginosa, use 2 g every 6-8 hours initially and consider combination therapy 1, 12.
Elderly patients: Renal function may be overestimated by serum creatinine alone. Calculate creatinine clearance and adjust doses accordingly 1.
Extended infusions: For optimal pharmacodynamics, consider 3-hour infusions for severe infections, particularly in critically ill patients 13.
Aztreonam-avibactam combination: When treating MBL-producing organisms, the combination requires specific dosing (not covered by standard aztreonam monotherapy guidelines) and should be guided by infectious disease consultation 5, 6.